161. 家族性良性慢性天疱瘡 Disease details / Clinical trials / Drug dev / DR info /
臨床試験数 : 5 / 薬物数 : 9 - (DrugBank : 4) / 標的遺伝子数 : 2 - 標的パスウェイ数 : 24
薬物ごとの開発者(Primary Sponsor)、臨床試験情報(抜粋)です。
(E)-1-(4-((1R,2S,3R)-1,2,3,4-tetrahydroxybutyl)-1H-imidazol-2-yl)ethanone oxime
Dermecular Therapeutics, Inc.
2018 Phase 1;Phase 2 EUCTR2018-000373-80-FR France;
Botulism Toxin Treatment
University Hospital, Toulouse
2015 Phase 1 NCT02782702 -
Celecoxib
Juntendo university gradurate school of medicine
2013 - JPRN-UMIN000010191 Japan;
Doxycycline
Gangnam Severance Hospital
2020 - NCT05007223 Korea, Republic of;
LX3305 250 mg capsule
Dermecular Therapeutics, Inc.
2018 Phase 1;Phase 2 EUCTR2018-000373-80-FR France;
None
Dermecular Therapeutics, Inc.
2018 Phase 1;Phase 2 EUCTR2018-000373-80-FR France;
Dermecular Therapeutics, Inc.
2018 Phase 1;Phase 2 EUCTR2018-000373-80-FR France;
Botulism Toxin Treatment
University Hospital, Toulouse
2015 Phase 1 NCT02782702 -
Celecoxib
Juntendo university gradurate school of medicine
2013 - JPRN-UMIN000010191 Japan;
Doxycycline
Gangnam Severance Hospital
2020 - NCT05007223 Korea, Republic of;
LX3305 250 mg capsule
Dermecular Therapeutics, Inc.
2018 Phase 1;Phase 2 EUCTR2018-000373-80-FR France;
None
Dermecular Therapeutics, Inc.
2018 Phase 1;Phase 2 EUCTR2018-000373-80-FR France;